What does PhaseV do?
PhaseV provides a vertical AI platform that supports end-to-end clinical development from design to execution. The platform includes four core applications and has been used by more than 30 pharma and biotech sponsors across diverse therapeutic areas.
How much did they raise?
The company raised $50M in a Series A round, co-led by Accel and Insight Partners with participation from Viola Ventures, EXOR, and LionBird. This round brings its total funding to $65M.
What are their plans for the money?
With the new funds, PhaseV intends to expand its operations and further develop its AI-driven solutions, aiming to enhance clinical development processes across various therapeutic areas.
What have they achieved so far?
PhaseV has already demonstrated significant impact by delivering successful results for over 30 pharma and biotech sponsors in fields such as neurology, oncology, immunology, and rare diseases.
